Department of Hematology, Sapporo Kiyota Hospital, Sapporo, Japan.
Mod Rheumatol Case Rep. 2021 Jul;5(2):195-199. doi: 10.1080/24725625.2020.1857008. Epub 2020 Dec 14.
An 84-year-old woman, who was diagnosed with rheumatoid arthritis (RA) and was treated with methotrexate and, subsequently, etanercept (ETN) for 6 years, presented with rapidly progressing painful cutaneous mass on the right medial malleolus. The patient was eventually diagnosed with primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT). ETN therapy was promptly discontinued expecting spontaneous regression of the lymphoma, which was thought to have developed as other iatrogenic immunodeficiency-associated lymphoproliferative disorders. However, no tumour regression was noted. Chemoimmunotherapy was subsequently initiated, which resulted in partial remission. PCLBCL-LT rarely occurs in patients with RA. Here, we report the first case of PCLBCL-LT that developed in a patient with RA receiving ETN therapy.
一位 84 岁女性,患有类风湿关节炎(RA),曾接受甲氨蝶呤和依那西普(ETN)治疗 6 年,现出现右侧内踝部快速进展性疼痛性皮肤肿块。患者最终被诊断为原发性皮肤弥漫性大 B 细胞淋巴瘤,腿型(PCLBCL-LT)。为了期待淋巴瘤自发消退,迅速停用了 ETN 治疗,因为人们认为这是其他医源性免疫缺陷相关淋巴增生性疾病。然而,没有观察到肿瘤消退。随后启动了化疗免疫治疗,结果部分缓解。PCLBCL-LT 在 RA 患者中很少见。在此,我们报告首例接受 ETN 治疗的 RA 患者发生的 PCLBCL-LT。